Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Prostate Cancer

  Free Subscription


1 Acta Radiol
1 Am J Clin Pathol
1 Am J Surg Pathol
2 Anticancer Res
2 BJU Int
1 Clin Cancer Res
1 Eur Urol
1 Int J Radiat Oncol Biol Phys
1 Int J Urol
1 J Clin Oncol
8 J Urol
1 Nat Rev Urol
3 Oncol Rep
1 Proc Natl Acad Sci U S A
1 Prostate
2 Urology

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Acta Radiol

  1. GIANNARINI G, Cereser L, Como G, Bonato F, et al
    Accuracy of abbreviated multiparametric MRI-derived protocols in predicting local staging of prostate cancer in men undergoing radical prostatectomy.
    Acta Radiol. 2020 Jul 27:284185120943047. doi: 10.1177/0284185120943047.
    PubMed         Abstract available

    Am J Clin Pathol

  2. WANG Q, Chen F, Jiang D, Kabani A, et al
    Prostate-Specific Antigen Test Utilization in a Major Canadian City.
    Am J Clin Pathol. 2020;153:776-780.
    PubMed         Abstract available

    Am J Surg Pathol

  3. GANDHI JS, Smith SC, Paner GP, McKenney JK, et al
    Reporting Practices and Resource Utilization in the Era of Intraductal Carcinoma of the Prostate: A Survey of Genitourinary Subspecialists.
    Am J Surg Pathol. 2020;44:673-680.
    PubMed         Abstract available

    Anticancer Res

  4. BUWENGE M, Deodato F, Dominsky N, Ntreta M, et al
    Radiotherapy of Prostate Carcinoma: A Comparison of the Predictive Role of EAU Versus NCCN Risk Stratification Systems.
    Anticancer Res. 2020;40:4413-4418.
    PubMed         Abstract available

  5. SHIMURA Y, Suga Y, Itai S, Iwamoto H, et al
    Comparison of Tolerability Between 2-Weekly and 3-Weekly Docetaxel Regimen in Castration-resistant Prostate Cancer.
    Anticancer Res. 2020;40:4291-4297.
    PubMed         Abstract available

    BJU Int

  6. FRANCOLINI G, Jereczek-Fossa BA, Di Cataldo V, Simontacchi G, et al
    Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series.
    BJU Int. 2020;125:417-425.
    PubMed         Abstract available

    Prostate cancer screening and treatment: where have we come from and where are we going?
    BJU Int. 2020 Jul 27. doi: 10.1111/bju.15153.
    PubMed         Abstract available

    Clin Cancer Res

  8. GUAN X, Sun D, Lu E, Urrutia JA, et al
    Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
    Clin Cancer Res. 2020 Jul 29. pii: 1078-0432.CCR-19-2303.
    PubMed         Abstract available

    Eur Urol

  9. STAVRINIDES V, Giganti F, Emberton M, Moore CM, et al
    Reply to Francesco Montorsi, Giorgio Gandaglia, Nicola Fossati, Andrea Salonia, and Alberto Briganti's Letter to the Editor re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active S
    Eur Urol. 2020 Jul 22. pii: S0302-2838(20)30542.

    Int J Radiat Oncol Biol Phys

  10. PARRY MG, Nossiter J, Cowling TE, Sujenthiran A, et al
    Toxicity of pelvic lymph node irradiation with intensity modulated radiation therapy for high-risk and locally advanced prostate cancer: a national population-based study using patient-reported outcomes.
    Int J Radiat Oncol Biol Phys. 2020 Jul 24. pii: S0360-3016(20)31450.
    PubMed         Abstract available

    Int J Urol

  11. IPPOLITO D, Querques G, Pecorelli A, Perugini G, et al
    Diagnostic accuracy of multiparametric magnetic resonance imaging combined with clinical parameters in the detection of clinically significant prostate cancer: A novel diagnostic model.
    Int J Urol. 2020 Jul 25. doi: 10.1111/iju.14316.
    PubMed         Abstract available

    J Clin Oncol

  12. EASTHAM JA, Heller G, Halabi S, Monk JP 3rd, et al
    Cancer and Leukemia Group B 90203 (Alliance): Radical Prostatectomy With or Without Neoadjuvant Chemohormonal Therapy in Localized, High-Risk Prostate Cancer.
    J Clin Oncol. 2020 Jul 24:JCO2000315. doi: 10.1200/JCO.20.00315.
    PubMed         Abstract available

    J Urol

    Re: Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men with Locally Advanced Prostate Cancer: 10-Year Data from the TROG 03.04 RADAR Trial.
    J Urol. 2020 Jul 27:101097JU000000000000122002.

  14. ATALA A
    Re: OXPHOS Remodeling in High-Grade Prostate Cancer Involves mtDNA Mutations and Increased Succinate Oxidation.
    J Urol. 2020 Jul 24:101097JU0000000000001222. doi: 10.1097/JU.0000000000001222.

    Re: Olaparib for Metastatic Castration-Resistant Prostate Cancer.
    J Urol. 2020 Jul 27:101097JU0000000000001220. doi: 10.1097/JU.0000000000001220.

    Re: Prostate-Specific Membrane Antigen PET-CT in Patients with High-Risk Prostate Cancer before Curative-Intent Surgery or Radiotherapy (proPSMA): A Prospective, Randomised, Multicentre Study.
    J Urol. 2020 Jul 27:101097JU000000000000122001.

  17. WANG AZ, O'Connor LP, Yerram NK, Long L, et al
    PIRADS Category as a Predictor of Progression to Unfavorable Risk Prostate Cancer in Men on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001307. doi: 10.1097/JU.0000000000001307.
    PubMed         Abstract available

  18. SONG G, Ruan M, Wang H, Fan Y, et al
    How Many Targeted Biopsy Cores are Needed for Clinically Significant Prostate Cancer Detection during Transperineal Magnetic Resonance Imaging Ultrasound Fusion Biopsy?
    J Urol. 2020 Jul 27:101097JU0000000000001302. doi: 10.1097/JU.0000000000001302.
    PubMed         Abstract available

  19. GREGG JR, Surasi DS, Childs A, Moll N, et al
    The Association of Peri-Prostatic Fat and Grade Group Progression in Men with Localized Prostate Cancer on Active Surveillance.
    J Urol. 2020 Jul 27:101097JU0000000000001321. doi: 10.1097/JU.0000000000001321.
    PubMed         Abstract available

  20. PARK KJ, Choi SH, Lee JS, Kim JK, et al
    Risk Stratification of Prostate Cancer According to PI-RADS Version 2 Categories: Meta-Analysis for Prospective Studies.
    J Urol. 2020 Jul 27:101097JU0000000000001306. doi: 10.1097/JU.0000000000001306.
    PubMed         Abstract available

    Nat Rev Urol

  21. SHARPLEY CF, Christie DRH, Bitsika V
    Depression and prostate cancer: implications for urologists and oncologists.
    Nat Rev Urol. 2020 Jul 30. pii: 10.1038/s41585-020-0354.
    PubMed         Abstract available

    Oncol Rep

    MDM2 as a target for ellagic acidmediated suppression of prostate cancer cells in vitro.
    Oncol Rep. 2020;44:1255-1265.
    PubMed         Abstract available

  23. WANG F, Wang W, Lu L, Xie Y, et al
    MicroRNA165p regulates cell survival, cell cycle and apoptosis by targeting AKT3 in prostate cancer cells.
    Oncol Rep. 2020;44:1282-1292.
    PubMed         Abstract available

  24. HUO W, Qi F, Wang K
    Long noncoding RNA BCYRN1 promotes prostate cancer progression via elevation of HDAC11.
    Oncol Rep. 2020;44:1233-1245.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  25. Correction to Supporting Information for Zadra et al., Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2020 Jul 27. pii: 2012767117.


  26. AHMED ME, Andrews JR, Alamiri J, Higa J, et al
    Adding carboplatin to chemotherapy regimens for metastatic castrate-resistant prostate cancer in postsecond generation hormone therapy setting: Impact on treatment response and survival outcomes.
    Prostate. 2020 Jul 31. doi: 10.1002/pros.24048.
    PubMed         Abstract available


  27. CIPRUT SE, Kelly MD, Walter D, Hoffman R, et al
    A Clinical Reminder Order Check (CROC) Intervention to Improve Guideline-Concordant Imaging Practices for men with Prostate Cancer: A Pilot Study.
    Urology. 2020 Jul 25. pii: S0090-4295(20)30888.
    PubMed         Abstract available

  28. BARQAWI A, Pessoa RR, Al-Musawi M, MacDermott T, et al
    Urology. 2020 Jul 22. pii: S0090-4295(20)30867.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.